Oral Semaglutide to be Assessed for Liver Fat in Transplant Recipients with Diabetes
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
Background
Nonalcoholic fatty liver disease (NAFLD), encompassing liver steatosis to cirrhosis, is intimately linked to insulin resistance, obesity, and type 2 diabetes. A significant concern is the development of NAFLD in transplanted livers, driven by persistent risk factors like decreased physical activity, oral steroids, and immunosuppressants in post-transplant patients. Currently, there are no approved medications for NAFLD. Semaglutide, a GLP-1 receptor agonist approved for diabetes and obesity, has shown beneficial effects on NAFLD, but its impact in post-liver transplant patients remains unexplored.